Loading...
Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model.
Yang, Taihua Poenisch, Marion Khanal, Rajendra Hu, Qingluan Dai, Zhen Li, Ruomeng Song, Guangqi Yuan, Qinggong Yao, Qunyan Shen, Xizhong
Yang, Taihua
Poenisch, Marion
Khanal, Rajendra
Hu, Qingluan
Dai, Zhen
Li, Ruomeng
Song, Guangqi
Yuan, Qinggong
Yao, Qunyan
Shen, Xizhong
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2021-08-25
Submitted date
Files
Loading...
Open Access publication
Adobe PDF, 20.27 MB
Loading...
supplemental material
Adobe PDF, 18.53 MB
Other Titles
Abstract
Background & aims: Therapeutic targeting of injuries that require transient restoration of proteins by mRNA delivery is an attractive approach that, until recently, has remained poorly explored. In this study, we examined the therapeutic utility of mRNA delivery for liver fibrosis and cirrhosis. Specifically, we aimed to demonstrate the therapeutic efficacy of human hepatocyte nuclear factor alpha (HNF4A) mRNA in mouse models of fibrosis and cirrhosis. Methods: We investigated restoration of hepatocyte functions by HNF4A mRNA transfection in vitro, and analyzed the attenuation of liver fibrosis and cirrhosis in multiple mouse models, by delivering hepatocyte-targeted biodegradable lipid nanoparticles (LNPs) encapsulating HNF4A mRNA. To identify potential mechanisms of action, we performed microarray-based gene expression profiling, single-cell RNA sequencing, and chromatin immunoprecipitation. We used primary liver cells and human liver buds for additional functional validation. Results: Expression of HNF4A mRNA led to restoration of the metabolic activity of fibrotic primary murine and human hepatocytes in vitro. Repeated in vivo delivery of LNP-encapsulated HNF4A mRNA induced a robust inhibition of fibrogenesis in 4 independent mouse models of hepatotoxin- and cholestasis-induced liver fibrosis. Mechanistically, we discovered that paraoxonase 1 is a direct target of HNF4A and it contributes to HNF4A-mediated attenuation of liver fibrosis via modulation of liver macrophages and hepatic stellate cells. Conclusion: Collectively, our findings provide the first direct preclinical evidence of the applicability of HNF4A mRNA therapeutics for the treatment of fibrosis in the liver. Lay summary: Liver fibrosis and cirrhosis remain unmet medical needs and contribute to high mortality worldwide. Herein, we take advantage of a promising therapeutic approach to treat liver fibrosis and cirrhosis. We demonstrate that restoration of a key gene, HNF4A, via mRNA encapsulated in lipid nanoparticles decreased injury in multiple mouse models of fibrosis and cirrhosis. Our study provides proof-of-concept that mRNA therapy is a promising strategy for reversing liver fibrosis and cirrhosis.
Citation
J Hepatol. 2021 Aug 25:S0168-8278(21)02006-7. doi: 10.1016/j.jhep.2021.08.011. Epub ahead of print.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
EISSN
1600-0641
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution-NonCommercial-NoDerivatives 4.0 International